Tiziana Life Sciences is trading 5.14% higher at $1.12 on October 6, 2026; no confirmed catalyst for the intraday rise was found. - Its latest releases were the September 30 FDA orphan-drug designation filing and September 28 trial dosing announcement; neither clearly explains the move. - The broader market is higher, while the provided biotech-sector context is negative, leaving the reason for the gain uncertain.